# A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

> **NCT01681134** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Canada, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Advagraf®
- **DRUG:** Prograf®

## Key facts

- **NCT ID:** NCT01681134
- **Lead sponsor:** Astellas Pharma Canada, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01681134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01681134, "A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01681134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*